MEMPHIS, Tenn. (Nov. 7) – Ariste Medical, Inc. has been awarded a second U.S. patent (#8,568,763) covering compositions and coatings for drug delivery. This patent furthers the intellectual property holdings of Ariste Medical in the realm of drug eluting coatings applicable to commonly used implantable medical devices, such as hernia mesh, vascular grafts, catheters, and similar devices that are subject to risk of infection, restenosis, and thrombosis. Ariste continues to develop novel approaches to the combination of drugs and devices in order to develop valuable tools for use in common surgical procedures.
MEMPHIS, Tenn. (October 29, 2012) – Ariste Medical, Inc., announced today that a key patent has been issued by the United States Patent and Trademark Office (USPTO). The U.S. patent (#8,236,338) covers a formulation capable of coating polytetrafluoroethylene (PTFE) and expanded PTFE, more commonly known as Teflon® and Gore-Tex®, respectively. The novel coating is capable of incorporating multiple pharmaceutical agents, enabling surgically implantable medical devices made from PTFE or ePTFE to also be used as drug-delivery devices. Ariste is presently developing a drug-eluting vascular graft for the prevention of restenosis-induced graft failure in hemodialysis patients.
Ariste has completed pre-clinical models demonstrating proof-of-concept using ePTFE grafts coated with rapamycin and has achieved a significant reduction in neointimal hyperplasia, or scarring within the graft. Ariste believes that its technology will help prevent graft failure in the hemodialysis setting, where failure is common and more than $1 billion dollars is incurred annually to reopen or repair vascular access sites so that patients can continue to receive dialysis treatment.
In addition, Ariste has raised $1.275 million in seed capital to advance the vascular graft program and to expand this technology to additional implantable devices made from PTFE or ePTFE.